Loading
Life sciences · Journal article
Frontiers in Aging · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Aging reshapes the tumor microenvironment (TME) by altering the immune, stromal, and vascular compartments, yet these changes are not fully explained by chronological age. Epigenetic mechanisms, including DNA methylation, histone modifications, chromatin accessibility, and non-coding RNA programs, may contribute to persistent alterations in cellular function and communication. In this review, we synthesize current evidence on epigenetic remodeling in the aged TME, distinguishing established findings in aging and cancer from mechanisms that remain to be demonstrated specifically in aged tumors. We highlight how epigenetic changes intersect with cellular senescence, chronic inflammation, and metabolic stress to weaken antitumor immunity and influence treatment response, with particular attention to T-cell dysfunction, regulatory T-cells, myeloid cells, fibroblasts, and endothelial cells. We also discuss the limitations of bulk-tissue epigenetic clocks and the emerging value of cell-resolved and spatial analyses. Finally, we consider therapeutic implications, including epigenetic therapies, senescence-directed interventions, and selective targeting of suppressive immune-stromal interactions, while noting that their ability to reverse TME aging remains uncertain. Integrating longitudinal human studies with functional experiments will be essential to determine whether epigenetically altered immune-stromal niches can serve as biomarkers or therapeutic targets beyond chronological age alone.